The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021.
Two half-day sessions are organized around prenatal screening, diagnosis, and therapies for ATM pregnancies (Day 1); and postnatal management of ATM from birth to adulthood (Day 2). Participants will include clinicians, scientists, and families affected by ATM.
If left untreated, a fetus with Alpha Thalassaemia Major will develop severe anemia and hydrops and will die before or shortly after birth. However, recent evidence from patient registries has demonstrated that when ATM is diagnosed early in pregnancy, in utero transfusions (IUT) can reverse hydrops and enable survival with good neurological outcomes.
The Conference aims to demonstrate the impact of prenatal therapy on postnatal and long-term outcomes of Alpha Thalassemia Major (ATM), understand best practices for prenatal and postnatal treatment of ATM, bring together families affected by ATM to share their diagnosis and treatment journeys, and build international connections among scientists, medical professionals, and patient advocates to advance treatments for ATM worldwide.
Read the Virtual Conference Full Programme HERE
Register in the Virtual Conference HERE